The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

Is compounded semaglutide effective for weight loss? Here’s the short version: Compounded semaglutide isn’t approved by the ...

We read with interest the article by Marie Lund and colleagues published in The Lancet Oncology investigating the association ...

The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, and cardiovascular ...

Patients with T2D are at higher risk for adverse pregnancy outcomes like preeclampsia, preterm birth, and neonatal ...

Katharine Lang reports Glucagon-like peptide-1 (GLP-1) receptor agonist drugs such as liraglutide (Saxenda) and semaglutide (Ozempic ... of younger people with obesity? Yes, says Julian ...

Manchester United have made an official bid for Lecce star Patrick Dorgu, and the club’s president has revealed all on what was said in the meeting. The Red Devils are desperate to sign a left ...

A recent JAMA Network Open study investigated the factors associated with semaglutide initiation among obese adults without diabetes ... and cardiovascular disease prevention. Obesity, often ...

We plan to hold the Journal Club on the fourth Wednesday of alternate months starting in January. They are exclusively for DOCP Members and will not be recorded. The Journal Club is an ideal way to ...

Opens in a new tab or window Patients treated with semaglutide ... biochemical and clinical outcomes after medical treatment for primary aldosteronism. (Lancet Diabetes & Endocrinology) Unadjusted ...

Semaglutide (known ... since the prevalence of obesity in people with type 1 diabetes is increasing and is associated with the risk of cardiovascular disease and complications.